title: Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial.
abstract: The clinical efficacy of a recombinant feline interferon (IFN) (type omega) was evaluated under field conditions for the treatment of dogs with parvoviral enteritis. In this multicentric, double-blind, placebo-controlled trial, 94 dogs from one to 28 months old were randomly assigned to two groups which were treated intravenously either with IFN (2.5 million units/kg) or placebo once a day for three consecutive days, and monitored for clinical signs and mortality for 10 days. Each dog received individual supportive treatment The data from 92 interpretable cases (43 IFN-treated and 49 placebo) showed that the clinical signs of the IFN-treated animals improved significantly in comparison with the control animals, and that there were only three deaths in the IFN group compared with 14 deaths in the placebo group (P = 0.0096) corresponding to a 4.4-fold reduction. Alternative analyses of the data taking into account the prior vaccination status of the dogs against canine parvovirus suggested that the IFN therapy resulted in a 6.4-fold reduction in mortality (P = 0.044) in the unvaccinated cohort, a significant reduction when compared with the vaccinated cohort.
authors.affiliation: Department of Research and Development, Laboratory Virbac BP27, 06511 Carros, France.
authors.forename: K
authors.initials: K
authors.lastname: de Mari
authors.forename: L
authors.initials: L
authors.lastname: Maynard
authors.forename: H M
authors.initials: HM
authors.lastname: Eun
authors.forename: B
authors.initials: B
authors.lastname: Lebreux
mesh_terms: D000818:Animals; D001831:Body Temperature; D004283:Dog Diseases / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D004285:Dogs; D004751:Enteritis / Q000188:drug therapy* / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D005260:Female; D007167:Immunotherapy; D007370:Interferon Type I / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D008297:Male; D010322:Parvoviridae Infections / Q000188:drug therapy* / Q000276:immunology / Q000662:veterinary*; D017993:Parvovirus, Canine; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D014765:Viral Vaccines / Q000276:immunology
chemical_list: D007370:Interferon Type I; D014765:Viral Vaccines; C063743:interferon omega 1